Simvastatin for the Treatment of Chronic Hepatitis B

Completed · Phase 1

Conditions studied: Hepatitis B

In brief

The investigators have shown robust in vitro anti-hepatitis B activity of simvastatin alone and synergistic activity with all four FDA-approved anti-hepatitis B oral drugs tested. The investigators propose phase 1 studies in 48 chronic hepatitis B human carriers who have never been treated before. Doses of drugs will remain at or below FDA-approved dosage levels for cholesterol lowering (simvastatin) or hepatitis B (tenofovir or entecavir). Arm 1 will have simvastatin monotherapy only. Arm 2 will combine simvastatin with tenofovir. Arm 3 will combine simvastatin with entecavir. For maximum safety, the 3 arms and the dose groups in each arm will be filled consecutively and not concurrently. The definition of efficacy for simvastatin alone will be a 1 log drop of hepatitis B virus in 14 days. Efficacy for combination of drugs will require a 2 log drop of hepatitis B virus in 14 days. Numerous safety tests and stop rules are noted in the protocol.

Key facts

Study ID

NCT00994773

Run by

Bader, Ted, M.D.

People needed

32

Starts

2009-12-01

Expected to finish

2011-12-01

Last updated by the study team

2012-08-16

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hepatitis B positive by HBV DNA within 180 days.
• Ages 18-70.
• Men and non-pregnant women eligible.
• Veteran's eligibility or appropriate health insurance.

You may not qualify if…

• Use of any anti-HBV medicine within 30 days.
• Decompensated cirrhosis as evidenced by esophageal varices, ascites, or encephalopathy. (grade 1 varices without history of bleeding will be allowed, if patient meets Child's-Pugh functional classification grade A).
• A positive urine test for marijuana or alcohol within 2 months of screening.(Allowed to repeat tests on different days, if positive first time in order to become eligible for study.
• Severe cardiovascular disease (ejection fraction <20%)* or uncontrolled angina.
• Severe pulmonary disease (FEV1 < 1.0).
• Chronic renal insufficiency (creatinine clearance <50 ml/min.
• HIV positive patients.

Where it is running

• VA Medical Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.